Stocks and Investing Stocks and Investing
Wed, May 4, 2022

Matthew Harrison Maintained (BIIB) at Buy with Increased Target to $285 on, May 4th, 2022


Published on 2024-10-27 20:49:29 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $283 to $285 on, May 4th, 2022.

Matthew has made no other calls on BIIB in the last 4 months.



There are 12 other peers that have a rating on BIIB. Out of the 12 peers that are also analyzing BIIB, 7 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $223 on, Tuesday, March 8th, 2022
  • Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $270 on, Thursday, April 21st, 2022
  • Mohit Bansal of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $265 on, Monday, April 18th, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $262 on, Friday, April 8th, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Monday, February 7th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022
Contributing Sources